Haemonetics Corporation, a medical device company based in Boston, Massachusetts, has announced its acquisition of Vivasure Medical, a medtech firm located in Galway, for a deal valued at up to €185 million. This strategic move aims to enhance the scaling of Vivasure’s innovative PerQseal technologies, which are designed for minimally invasive vessel closure in various medical fields including cardiology and vascular surgery.
Founded in 2009 and supported by Enterprise Ireland, Vivasure Medical specializes in the development of the PerQseal device. This technology allows for the sealing of blood vessels from the inside, which is particularly valuable in interventional radiology and vascular surgery contexts. Currently, the use of PerQseal and its advanced version, PerQseal Elite, is not approved in the United States. Nonetheless, Vivasure Medical has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for the PerQseal Elite system.
Andrew Glass, CEO of Vivasure Medical, expressed pride in the company’s advancements in closure technology. “We’re extremely proud of the progress made in advancing closure technology, and grateful to the clinicians who supported Vivasure’s mission,” he stated. He emphasized that joining Haemonetics will provide the necessary global scale and resources to expedite the availability of the PerQseal Elite system, expanding its benefits to more healthcare providers and patients worldwide.
In addition, Ger Brett, the COO and co-founder of Vivasure Medical, acknowledged the hard work of the company’s employees and founders. He also highlighted the crucial support from the board, investors, and government bodies throughout their journey. “We’re proud to make PerQseal in Ireland and distribute it around the world,” Brett noted.
The relationship between the two companies began in 2022, when Haemonetics made a strategic investment in Vivasure Medical, which included an option for future acquisition. In 2023, the collaboration deepened with an additional funding of €30 million from Haemonetics to further develop Vivasure’s vessel closure technology.
As the medtech industry continues to evolve rapidly, this acquisition represents a significant step for both Haemonetics and Vivasure Medical. The integration of Vivasure’s advanced technologies with Haemonetics’ extensive resources is anticipated to accelerate innovation in the field of vascular closure systems, ultimately enhancing patient outcomes across various medical disciplines.
